Support teaching, research, and patient care.
Research interests include:Biomarkers and targeted therapy in pediatric immune thrombocytopeniaTransfusion-related iron overloadHemophilia and other rare bleeding disordersThrombophilia
Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE) Not Recruiting
This is a Phase III clinical trial to compare the efficacy of two dosages of a new infant rehabilitation protocol - I-ACQUIRE - to usual and customary forms of infant rehabilitation in infants who experienced Perinatal Arterial Stroke (PAS).
Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
View full details
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment Not Recruiting
The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
Stanford is currently not accepting patients for this trial. For more information, please contact Spectrum Child Health, 650-724-1175.
Evaluation of the Duration of Therapy for Thrombosis in Children Not Recruiting
The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3 months) anticoagulation in children with first-episode acute venous thrombosis. The first stage of the trial has consisted of a pilot/feasibility component, which then continues as the definitively-powered trial.
Stanford is currently not accepting patients for this trial. For more information, please contact Clara Lo, 650-723-5535.
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP Not Recruiting
The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.
Stanford is currently not accepting patients for this trial. For more information, please contact Michael Jeng, 6507361177.